Monthly obstetrics and gynecology bulletin — October 12, 2026
This issue covers October 2 to 12, 2026, the eleven days since the previous issue (October 1). It is a short period and carries seven verified items; two come from outside North America and Western Europe (Dominican Republic and South Korea).
Obstetrics and maternal-fetal medicine
1. Quadrivalent HPV vaccination before pregnancy: less preterm birth in Swedish national registers
[Publication] [Sweden]
Population-based matched case-control study using Swedish national registers: 624,713 singleton births to nulliparous women aged 16 to 35 years between 2006 and 2023, of whom 92,620 (14.8%) had received the quadrivalent vaccine before pregnancy. After adjustment (smoking, BMI, maternal diagnoses, assisted reproduction, country of birth, income, and education), vaccination was associated with lower odds of preterm birth (aOR 0.95; 95% CI 0.91-0.99), very preterm birth at 28 to 31 weeks (aOR 0.85; 0.75-0.97), spontaneous preterm birth (aOR 0.95; 0.91-0.99), and severe small for gestational age, below the 3rd centile (aOR 0.92; 0.87-0.97). The reduction was generally greater in women vaccinated before age 17 (preterm birth: aOR 0.90; 0.85-0.95). Published online in The BMJ on October 7.
Why it matters: the study is observational, the effects are small, and residual confounding (vaccinated women differ from unvaccinated women in more than the vaccine) cannot be excluded; even so, it is consistent with the expected mechanism (fewer cervical lesions and fewer conizations) and adds an obstetric argument for early vaccination, at the ages already covered by vaccination programs for girls and adolescents.
https://www.bmj.com/content/395/bmj-2026-100739
2. Dominican Republic: 112 cumulative maternal deaths through epidemiological week 38
[Epidemiological surveillance] [Dominican Republic]
According to the latest bulletin of the Directorate of Epidemiology of the Ministry of Public Health, as reported by Diario Libre on October 8, the country has recorded 112 maternal deaths in 2026 through week 38 (109 before that week): 58 among Haitian women, 52 among Dominican women, and 2 among women of other nationalities. Week 38 had three maternal deaths (Santo Domingo, La Vega, and Montecristi). Cumulative infant deaths total 1,448, of which 1,214 (84%) occurred before 28 days of life.
Why it matters: the data are preliminary and the report gives neither causes nor the comparison with 2025. In addition, the cumulative count of 98 through week 35 that we published on September 28 does not square with 109 at the end of week 37 at a pace of three to four deaths per week, which suggests late notification or reclassification; the reduction versus 2025 that we reported then (98 versus 125) should therefore be read with caution.
Gynecologic oncology
3. RACC trial: robot-assisted versus open radical hysterectomy, perioperative results
[Clinical trial] [Sweden / Europe]
Analysis of predefined secondary outcomes of the open-label randomized RACC trial, a European multicenter study sponsored by Karolinska Institutet: 900 women with early-stage cervical cancer (FIGO IB, excluding IB3, or IIA1), randomized to robot-assisted or open radical hysterectomy. Intraoperative complications occurred in 5.7% with robotic surgery versus 10.0% with open surgery (a difference driven mainly by less serious events; serious complications were uncommon and similar); 30-day complications were 33.4% versus 34.8%, with similar serious complications, readmissions, and reoperations. Quality of life at one month showed small differences in some measures, such as physical functioning and pain; most measures showed no clinically meaningful difference. Published online in JAMA Surgery on October 7.
Why it matters: it does not change practice. The primary outcome (recurrence-free survival) is still being followed and oncologic results will be reported separately; the authors state explicitly that these data should not be used to judge the oncologic safety of robotic surgery, the open question since the LACC trial. Fewer intraoperative complications did not translate into fewer postoperative complications or better overall recovery. Funders include the Swedish Cancer Society, KWF Dutch Cancer Society, Region Stockholm, the Nordic Cancer Union, and the Intuitive Foundation.
https://jamanetwork.com/journals/jamasurgery/fullarticle/2854885
https://news.ki.se/similar-recovery-after-robot-assisted-and-open-surgery-for-cervical-cancer
Reproduction and endocrinology
4. American College of Physicians guideline: hormone therapy as first-line treatment for vasomotor symptoms
[Guideline] [USA]
On October 5 the American College of Physicians announced the publication in Annals of Internal Medicine of its clinical guideline on pharmacologic treatment of perimenopausal and postmenopausal vasomotor symptoms. First line (recommendation): estrogen combined with a progestogen for women with a uterus and estrogen alone for women without a uterus. Second line (suggestion), for contraindication to or intolerance of estrogen: a serotonin-norepinephrine reuptake inhibitor (desvenlafaxine or venlafaxine). Third line (suggestion): an SSRI (escitalopram or paroxetine), gabapentin, or a neurokinin receptor antagonist (elinzanetant or fezolinetant).
Why it matters: this is an internal medicine guideline, not one from a gynecologic society, and the ACP press release does not give the certainty of evidence for each recommendation; that requires reading the full text. Its practical value is that it places the new, expensive drugs on the last rung, which supports the use of estrogens and venlafaxine in resource-limited settings such as ours.
https://www.acpjournals.org/doi/10.7326/ANNALS-26-01205
5. Transcutaneous electrical nerve stimulation (TENS) does not reduce pain at IUD insertion
[Clinical trial] [USA]
Double-blind, sham-controlled randomized trial (Mount Sinai, New York) of 99 participants undergoing placement of a levonorgestrel 52-mg or copper T380A IUD, assigned to active high-frequency TENS or sham stimulation. Mean pain at insertion on a 100-mm visual analog scale was 50.8 mm with active TENS versus 50.6 mm with sham; in nulliparous participants, 58.8 versus 59.3 mm. The difference was not statistically significant. Published online in the American Journal of Obstetrics and Gynecology on October 8 (Kus LH et al.).
Why it matters: this is a clean, sham-controlled negative result that spares investment in equipment with no benefit for this purpose; the main limitation is its size (99 women).
https://pubmed.ncbi.nlm.nih.gov/42849809/
https://www.ocacademy.in/blogs/tens-for-iud-insertion-pain-trial
6. Fezolinetant and actigraphy-measured sleep: preliminary analysis of OPTION-VMS
[Meeting] [Industry] [USA]
Second preliminary analysis of the observational phase 4 OPTION-VMS study (NCT06049797), in women prescribed nonhormonal therapy for vasomotor symptoms, presented on September 30 at the International Menopause Society 20th World Congress on Menopause and publicized by Astellas in a press release dated October 2: 993 women enrolled as of March 2026, 859 with a baseline and at least one post-baseline assessment. In the fezolinetant group at 12 weeks, wakefulness after sleep onset fell by 9.45 minutes (95% CI −13.93 to −4.96), nighttime awakenings fell by 2.61 (−4.07 to −1.15), and sleep efficiency rose by 1.95% (0.93 to 2.97). Two cases of mild, non-serious elevation of liver tests were reported, with no treatment or study discontinuation.
Why it matters: the press release comes from Astellas, the drug's manufacturer; the study has no comparison group (these are changes from baseline, and the authors state explicitly that it is not designed to compare treatments) and there is no peer-reviewed publication; a 9-minute improvement in wakefulness is statistically significant but of debatable clinical relevance.
Minimally invasive surgery and pelvic floor
7. Vaginal uterosacral ligament suspension: nonabsorbable suture fails less often at one year
[Publication] [South Korea]
Retrospective cohort of 310 patients who underwent vaginal hysterectomy with uterosacral ligament suspension for uterine prolapse, with one year of follow-up, at a tertiary center (Seoul National University), operated on between October 2016 and September 2022: 205 with nonabsorbable suture and 105 with delayed-absorbable suture. Composite surgical failure at one year (bulge symptoms, apical descent greater than half of total vaginal length, anterior or posterior descent beyond the hymen, or retreatment with surgery or pessary) was 13.7% with nonabsorbable suture versus 38.1% with delayed-absorbable suture (p < 0.01). Overall suture-related complications did not differ (p = 0.28), but those requiring intervention were more frequent with nonabsorbable suture (5.9% versus 1.0%; p = 0.04). Published online in the International Urogynecology Journal on October 7, open access.
Why it matters: the study is retrospective, single-surgeon, with groups operated on in sequential periods (delayed-absorbable suture was adopted after August 2020) and with baseline differences (point C, total vaginal length, concomitant posterior repair), so the difference may be inflated; even so, the magnitude is large and supports preferring permanent suture for apical suspension, accepting more interventions for suture complications. It has not been replicated outside that center.
https://link.springer.com/article/10.1007/s00192-026-06925-9
Upcoming meetings and dates
- The Menopause Society annual meeting: October 20 to 24, San Diego.
- ESMO 2026 (medical oncology, with gynecologic tumor sessions): from October 23, Madrid.
- ASRM 2026 Scientific Congress & Expo: October 24 to 28, Baltimore.
- AAGL 55th Global Congress on minimally invasive gynecologic surgery: November 13 to 16, Boston.
Ready-to-paste LinkedIn post
Monthly obstetrics and gynecology bulletin — October 12, 2026 7 verified items from October 2 to 12, from The BMJ, JAMA Surgery, Annals of Internal Medicine, AJOG and the International Urogynecology Journal. Three worth your time: • Quadrivalent HPV vaccination before pregnancy: among 624,713 first births in Sweden it was associated with less preterm birth (aOR 0.95) and very preterm birth (aOR 0.85). Observational; the effect is small and residual confounding is possible. • RACC trial, 900 patients with early-stage cervical cancer: robot-assisted radical hysterectomy had fewer intraoperative complications than open surgery (5.7% vs 10.0%) and similar 30-day rates (33.4% vs 34.8%). The oncologic outcome is still pending. • The American College of Physicians places hormone therapy first line for vasomotor symptoms and neurokinin antagonists third. The press release does not give the certainty of evidence for each recommendation. Full bulletin, with a critical reading of every study and links to its sources: https://boletinesmedicos.com/en/obgyn/2026-10-12.html #ObGyn #Obstetrics #Gynecology #HPV #Menopause
Ready-to-paste X (Twitter) post
HPV vaccination before pregnancy was tied to less very preterm birth (aOR 0.85; 624,713 births, Sweden). RACC: robotic vs open radical hysterectomy, 30-day complications 33.4% vs 34.8%. https://boletinesmedicos.com/en/obgyn/2026-10-12.html
Get every issue by email
Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.
Subscribe by email